Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases?

Archive ouverte

Bey, Karim | Deniaud, Johan | Dubreil, Laurence | Joussemet, Béatrice | Cristini, Joseph | Ciron, Carine | Hordeaux, Juliette | Le Boulc’h, Morwenn | Marche, Kévin | Maquigneau, Maud | Guilbaud, Michaël | Moreau, Rosalie | Larcher, Thibaut | Deschamps, Jack-Yves | Fusellier, Marion | Blouin, Veronique | Sevin, Caroline | Cartier, Nathalie | Adjali, Oumeya | Aubourg, Patrick | Moullier, Philippe | Colle, Marie-Anne

Edité par CCSD ; Cell Press -

International audience. The identification of the most efficient method for whole central nervous system targeting that is translatable to humans and the safest route of adeno-associated virus (AAV) administration is a major concern for future applications in clinics. Additionally, as many AAV serotypes were identified for gene introduction into the brain and the spinal cord, another key to human gene-therapy success is to determine the most efficient serotype. In this study, we compared lumbar intrathecal administration through catheter implantation and intracerebroventricular administration in the cynomolgus macaque. We also evaluated and compared two AAV serotypes that are currently used in clinical trials: AAV9 and AAVrh10. We demonstrated that AAV9 lumbar intrathecal delivery using a catheter achieved consistent transgene expression in the motor neurons of the spinal cord and in the neurons/glial cells of several brain regions, whereas AAV9 intracerebroventricular delivery led to a consistent transgene expression in the brain. In contrast, AAVrh10 lumbar intrathecal delivery led to rare motor neuron targeting. Finally, we found that AAV9 efficiently targets respiratory and skeletal muscles after injection into the cerebrospinal fluid (CSF), which represents an outstanding new property that can be useful for the treatment of diseases affecting both the central nervous system and muscle.

Suggestions

Du même auteur

Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders

Archive ouverte | Bey, Karim | CCSD

Adeno-associated virus (AAV) gene therapy constitutes a powerful tool for the treatment of neurodegenerative diseases. While AAVs are generally administered systemically to newborns in preclinical studies of neurological disorders...

Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates.

Archive ouverte | Zerah, Michel | CCSD

No treatment is available for early-onset forms of metachromatic leukodystrophy (MLD), a lysosomal storage disease caused by autosomal recessive defect in arylsulfatase A (ARSA) gene causing severe demyelination in central and per...

Long-term neurologic and cardiac correction in the Pompe disease mice by intrathecal gene therapy

Archive ouverte | Hordeaux, Juliette | CCSD

National audience. Pompe disease (glycogen storage disease type II) is a lysosomal storage disorder caused by acidalpha- glucosidase (GAA) deficiency leading to progressive accumulation of glycogen in the heart, mus...

Chargement des enrichissements...